Point72 Asia (Singapore) Pte. Ltd. Cue Biopharma, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $532 Billion
- Q3 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 24,098 shares of CUE stock, worth $30,122. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,098
Previous 53,027
54.56%
Holding current value
$30,122
Previous $65.8 Million
72.25%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding CUE
# of Institutions
52Shares Held
14.1MCall Options Held
14.4KPut Options Held
2.6K-
Bleichroeder LP New York, NY5MShares$6.25 Million1.28% of portfolio
-
Slate Path Capital LP New York, NY2.4MShares$3 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.03MShares$2.54 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$945,9200.0% of portfolio
-
Geode Capital Management, LLC Boston, MA509KShares$636,0330.0% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $44.2M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...